INFLUVAC (influenza vaccine, surface antigen, inactivated) - Influenza vaccine

The Committee considers that the clinical benefit of INFLUVAC (influenza vaccine, surface antigen, inactivated) is substantial in the prophylaxis of influenza in adults and children from 6 months of age in accordance with the current HAS vaccination recommendations dating from 12 December 2024.

The change from tetravalent to trivalent is not of a nature to modify the clinical added value. The Committee considers that INFLUVAC (influenza vaccine, surface antigen, inactivated) provides no clinical added value (CAV V), in adults and children from 6 months of age for whom vaccination is recommended, compared to the other vaccines recommended in the prevention of seasonal influenza.